60 Degrees Pharmaceuticals, Inc. SXTP 深 沪
等待开盘 10-31 09:30:00 美东时间
1.38
-0.020
-1.43%
华盛通- 最 高1.39
- 今 开1.38
- 成交量 4.57万股
- 最 低 1.35
- 昨 收 1.40
- 总市值 430.92万
- 52周最高 12.45
- 市盈率 静 --
- 换手率 1.46%
- 52周最低 1.215
- 委 比 -6.15%
- 总股本 312.26万
- 历史最高 519.00
- 量 比 0.54
- 振 幅 2.86%
- 历史最低 1.35
- 每 手 1
- 风险率 1.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
60 Degrees Pharmaceuticals, Inc. has submitted a Breakthrough Therapy Designation request to the FDA for tafenoquine, a malaria drug, targeting babesiosis treatment. The company is conducting clinical trials to confirm its efficacy in immunosuppressed patients with relapsing babesiosis. The first patient in their expanded access study tested negative for the infection using highly sensitive tests. Remaining patients will complete the study by Oct...
10-15 11:14
60 Degrees Pharma Launches B-FREE Study, First-Ever Trial for Chronic Babesiosis Treatment
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the name
10-09 19:18
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
60 Degrees Pharmaceuticals宣布启动名为B-FREE的慢性巴贝斯虫病II期临床试验，该研究旨在评估药物ARAKODA（tafenoquine）的效果。公司通过社交媒体邀请患者参与命名竞赛，最终选定B-FREE，并捐赠5000美元支持相关疾病研究机构。研究计划招募100名患者，评估药物疗效及安全性，预计11月初启动，持续约12个月。
10-09 11:04
60 Degrees Pharmaceuticals Enters New Sales Agreement
The latest update is out from 60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ). On ...
09-06 04:50
Alphabet To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-03 20:25
Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $3
Ascendiant Capital analyst Lucas Ward maintains 60 Degrees (NASDAQ:SXTP) with a Buy and lowers the price target from $7 to $3.
09-03 18:45
60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) announced its participation in the 27th Annual Global Investment Conference hosted by H.C. Wainwright (HCW) from September 8-10, 2025, at the Lotte New York Palace Hotel. Dr. Geoff Dow, CEO, will present live on September 10, 2:30 ET, with management available for 1x1 meetings. The presentation will be webcast live and available for replay for 90 days. For more information, visit the investor...
08-21 12:31
60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
60 Degrees Pharmaceuticals has signed a clinical trial agreement with Mount Sinai's Icahn School of Medicine to evaluate ARAKODA (tafenoquine) in treating chronic babesiosis, a debilitating illness with no FDA-approved treatment. The Phase II study will measure fatigue resolution in patients with at least six months of symptoms and assess the drug's safety and efficacy over 90 days. Enrollment is expected to commence in Q4 2025 and complete by Q2...
08-19 12:54
60 Degrees Q2 EPS $(1.25) Misses $(0.96) Estimate, Sales $101.000K Miss $301.000K Estimate
60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(0.96) by 30.21 percent. This is a 70.45 percent increase over losses of $(4.23) per share from the
08-14 04:19
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
60 Degrees Pharmaceuticals第二季度净产品收入同比下降19%，但因采用现金支付分销模式提高了盈利能力。公司拥有197万美元现金储备，预计可维持至2026年3月31日。尽管供应链中断影响了ARA-KODA 16盒装销量，但引入新的8盒装瓶和FDA批准的KODATEF 16盒装进口缓解了部分影响。公司还完成了几项商业研究，估计 babesiosis 的年度发病率在25,000至380,000例之间，预计未来10年内 ARK-O-D 的市场规模可能达到11亿美元。
08-13 20:14
